Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:11/10/2008

PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Rodman and Renshaw 10th Annual Global Investment Conference and the Lazard Capital Markets 5th Annual Healthcare Conference. Both conferences will be held in New York, NY.

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the Rodman and Renshaw Conference on Tuesday, November 11, 2008 at 12:25 PM (ET) and at the Lazard Capital Markets Conference on Tuesday November 18, 2008 at 8:55 AM (ET)

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for t
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
2. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
5. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
6. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
7. Pharmasset Joins Russell 3000 Index
8. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
9. Pharmasset Selected to Join the NASDAQ Biotechnology Index
10. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
11. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... biologically safer water through point-of-use ... ultrafiltration, ... ),a medical device company, announced today that it will be exhibiting ... Conference and Technical Exhibition in National Harbor,Maryland, July 20th-23rd, 2008. Building ...
... Revenues While Advancing Three Major Clinical Programs, and Securing ... ... Million -, TUSTIN, Calif., July 14 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... ended April 30, 2008. Total revenues for FY 2008,increased 64% to ...
... Raptor,Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today ... to the Company,s board of,directors and Stephen C. ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO ), Christopher M. ... stated, "I would like to welcome Drs. Franklin ...
Cached Biology Technology:Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 11Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 2Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 3Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 4Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 5
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... A major asthma discovery by a researcher at the ... licensed by MedImmune, a leading innovation-focused biotechnology company and ... the discovery to explore its use in the development ... Under the agreement, MedImmune was granted ...
... The availability of healthy food choices and your quality ... to two studies conducted by researchers at the Johns ... food availability and diet quality among Baltimore City and ... healthy foods was associated with quality of diet and ...
... Cutting edge science has finally put to rest a ... long-romanticized story of a child,s escape from the firing ... Medical School in cooperation with Institutions of ... Sciences (MHRC) have confirmed that human remains found ...
Cached Biology News:La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 2La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 3Healthy food availability could depend on where you live -- so does the quality of your diet 2Healthy food availability could depend on where you live -- so does the quality of your diet 3UMMS researchers publish DNA identification of czar's children 2UMMS researchers publish DNA identification of czar's children 3UMMS researchers publish DNA identification of czar's children 4
Request Info...
...
...
... cytostatic and anti-viral agent. Inhibits several important steps ... formation of HUVEC cells. Also reduces intracellular reactive ... IL-8 release of endothelial cells. ... 16 O 8 MolWeight: ...
Biology Products: